SJÖGREN'S DISEASE
Clinical trials for SJÖGREN'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new SJÖGREN'S DISEASE trials appear
Sign up with your email to follow new studies for SJÖGREN'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to halt lung damage in autoimmune patients
Disease control Recruiting nowThis study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…
Matched conditions: SJÖGREN'S DISEASE
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New biologic XmAb657 enters first human tests for autoimmune conditions
Disease control Recruiting nowThis early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…
Matched conditions: SJÖGREN'S DISEASE
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New monthly shot could ease Sjögren's dry mouth
Symptom relief Recruiting nowThis phase 3 study tests whether ianalumab, given as a monthly injection, can reduce dry mouth and other symptoms in people with Sjögren's disease who have a high symptom burden. About 570 adults will receive either the drug or a placebo for 52 weeks. The main goal is to see if t…
Matched conditions: SJÖGREN'S DISEASE
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
New eye drop battle: which offers better dry eye relief?
Symptom relief Recruiting nowThis study compares two preservative-free eye drops, Artelac Complete MDO and VISMED MULTI, for treating moderate to severe dry eye disease. About 160 adults who have used tear substitutes for at least a month will use one of the two drops for 90 days. Researchers will measure ch…
Matched conditions: SJÖGREN'S DISEASE
Phase: NA • Sponsor: Dr. Gerhard Mann chem.-pharm. Fabrik GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC